EFFECTS OF PROSTACYCLIN (PGI₂) AND ADENOSINE (ASN) ON TOTAL AND REGIONAL BLOOD FLOW OF ISOLATED, COLLATERALIZED DOG HEARTSSCHOLTHOLT J; BIRRINGER H; FIEDLER VB et al.1981; BASIC RES. CARDIOL.; ISSN 0300-8428; DEU; DA. 1981; VOL. 76; NO 3; PP. 313-327; BIBL. 49 REF.Article

ZUR PHARMAKOLOGIE DES BETA -REZEPTORENBLOCKERS PENBUTOLOL = PHARMACOLOGIE DE L'AGENT BETA -BLOQUANT PENBUTOLOLKAISER J; HARTFELDER G; LINDNER E et al.1980; ARZNEIMITTEL-FORSCH.; DEU; DA. 1980; VOL. 30; NO 3; PP. 420-427; ABS. ENG; BIBL. 24 REF.Article

EFFECT IN VIVO OF BETA -ADRENERGIC STIMULATION, ANGIOTENSIN II, DIBUTYRYL CYCLIC AMP, AND THEOPHYLLINE ON TONIN CONCENTRATION IN RAT SALIVA AND SUBMAXILLARY GLAND.GARCIA R; KONDO K; SCHOLKENS B et al.1977; CANAD. J. PHYSIOL. PHARMACOL.; CANADA; DA. 1977; VOL. 55; NO 5; PP. 983-989; ABS. FR.; BIBL. 1 P.Article

A specific B₂-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramiprilLINZ, W; SCHÖLKENS, B. A.British journal of pharmacology. 1992, Vol 105, Num 4, pp 771-772, issn 0007-1188Article

ACE inhibitors: PharmacologyGOHLKE, P; SCHÖLKENS, B. A.Handbook of experimental pharmacology. 2004, Vol 163, pp 375-413, issn 0171-2004, 39 p., 2Article

Cardioprotective effects of ACE inhibitors : experimental proof and clinical perspectivesSCHÖLKENS, B. A; LINZ, W.Clinical physiology and biochemistry. 1990, Vol 8, pp 33-43, issn 0252-1164, 11 p., Suppl. 1Conference Paper

Does bradykinin play a role in the cardiac antiischemic effect of the ACE-inhibitors ?MARTORANA, P. A; LINZ, W; SCHOLKENS, B. A et al.Basic research in cardiology. 1991, Vol 86, Num 4, pp 293-296, issn 0300-8428Article

Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in ratsLINZ, W; SCHÖLKENS, B. A; GANTEN, D et al.Clinical and experimental hypertension. Part A, Theory and practice. 1989, Vol 11, Num 7, pp 1325-1350, issn 0730-0077Article

Kinin receptor antagonists : unique probes in basic and clinical researchWIRTH, K. J; HEITSCH, H; SCHÖLKENS, B. A et al.Canadian journal of physiology and pharmacology. 1995, Vol 73, Num 7, pp 797-804, issn 0008-4212Conference Paper

Biological activities of 6-keto-prostaglandin E₁LEWIS, R; SCHÖLKENS, B. A; BECK, G et al.Prostaglandins leukotrienes and medicine. 1984, Vol 16, Num 3, pp 303-324, issn 0262-1746Article

Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigsWIRTH, K. J; GEHRING, D; SCHÖLKENS, B. A et al.The American review of respiratory disease. 1993, Vol 148, Num 3, pp 702-706, issn 0003-0805Article

ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat heartsLINZ, W; WIEMER, G; SCHÖLKENS, B. A et al.Journal of molecular and cellular cardiology. 1992, Vol 24, Num 8, pp 909-919, issn 0022-2828Article

The bradykinin B₂ receptor antagonist WIN 64338 inhibits the effect of des-Arg⁹-bradykinin in endothelial cellsWIRTH, K. J; SCHÖLKENS, B. A; WIEMER, G et al.European journal of pharmacology. Molecular pharmacology section. 1994, Vol 288, Num 1, pp R1-R2, issn 0922-4106Article

Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in ratsLINZ, W; HENNING, R; SCHÖLKENS, B. A et al.Journal of hypertension. 1991, Vol 9, pp S400-S401, issn 0263-6352, SUP6Conference Paper

Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissueLINZ, W; WIEMER, G; SCHÖLKENS, B. A et al.Arzneimittel-Forschung. 1988, Vol 38, Num 2, pp 240-243, issn 0004-4172Article

Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive ratsLINZ, W; HEITSCH, H; SCHOLKENS, B. A et al.Hypertension (Dallas, Tex. 1979). 2000, Vol 35, Num 4, pp 908-913, issn 0194-911XArticle

Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failureSCHOLKENS, B. A; MARTORANA, P. A; GOBEL, H et al.Clinical and experimental hypertension. Part A, Theory and practice. 1986, Vol 8, Num i6, pp 1033-1048, issn 0730-0077Article

Endothelial protection by converting enzyme inhibitors : The cardiovascular actions of converting enzyme inhibitorsWIEMER, G; SCHÖLKENS, B. A; LINZ, W et al.Cardiovascular research. 1994, Vol 28, Num 2, pp 166-172, issn 0008-6363Article

Regulation of aortic atrial natriuretic factor and angiotensinogen in experimental hypertensionOGAWA, T; LINZ, W; SCHÖLKENS, B. A et al.Journal of cardiovascular pharmacology. 1998, Vol 32, Num 6, pp 1001-1008, issn 0160-2446Article

Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cellsWIEMER, G; POPP, R; SCHÖLKENS, B. A et al.Brain research. 1994, Vol 638, Num 1-2, pp 261-266, issn 0006-8993Article

Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive ratsUNGER, T; GANTEN, D; LANG, R. E et al.Journal of cardiovascular pharmacology. 1985, Vol 7, Num 1, pp 36-41, issn 0160-2446Article

Novel series of o-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B₂ receptorsHEITSCH, H; WAGNER, A; SCHÖLKENS, B. A et al.Bioorganic & medicinal chemistry letters (Print). 1999, Vol 9, Num 3, pp 327-332, issn 0960-894XArticle

Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction = Clinical interest of low dose of converting enzyme inhibitor : the HYCAR studyLINZ, W; GOHLKE, P; UNGER, T et al.Archives des maladies du coeur et des vaisseaux. 1995, Vol 88, pp 31-34, issn 0003-9683, NS2Conference Paper

Variable renal atrial natriuretic factor gene expression in hypertensionOGAWA, T; LINZ, W; SCHÖLKENS, B. A et al.Hypertension (Dallas, Tex. 1979). 1999, Vol 33, Num 6, pp 1342-1347, issn 0194-911XArticle

Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? studies with the two different compounds Hoe498 and MK421, in spontaneously hypertensive ratsUNGER, T; GANTEN, D; LANG, R. E et al.Journal of cardiovascular pharmacology. 1984, Vol 6, Num 5, pp 872-880, issn 0160-2446Article